Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 3/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 9/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2596820 | 0.81 | L3MBTL1 (0.30) | L3MBTL1P2RX3 | |
| SCHEMBL2596788 | 0.79 | MET (0.44) | L3MBTL1METKDM4CP2RX3NPC1 | |
| SCHEMBL2598449 | 0.78 | L3MBTL1 (0.40) | L3MBTL1METKDM4CP2RX3NPC1 | |
| SCHEMBL2596744 | 0.73 | MEN1 (0.40) | L3MBTL1METKDM4CP2RX3NPC1 | |
| SCHEMBL28353872 | 0.70 | KDM4C (0.42) | L3MBTL1METKDM4CP2RX3NPC1 | |
| SCHEMBL19015255 | 0.70 | NPC1 (0.41) | L3MBTL1METKDM4CP2RX3NPC1 | |
| SCHEMBL26916099 | 0.69 | L3MBTL1 (0.39) | L3MBTL1KDM4CP2RX3NPC1RAB9A | |
| SCHEMBL2697838 | 0.69 | MET (0.50) | L3MBTL1METKDM4CP2RX3NPC1 | |
| SCHEMBL15742257 | 0.69 | KDM4C (0.38) | L3MBTL1METKDM4CP2RX3NPC1 | |
| SCHEMBL2631762 | 0.69 | MET (0.45) | L3MBTL1METKDM4CP2RX3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073918-B2 | Pyrazolo[4,3-b]pyridine-7-amine inhibitors of ALK5 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-07 | — | — | US | disclosed |
| US-20130324528-A1 | PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-05 | — | — | US | disclosed |
| WO-2011146287-A1 | PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324528-A1 | PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 | ALK, ALKBH5, ALKBH3 | L3MBTL1 4595/4885MET 475/4885KDM4C 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.